Intravitreal Quantum Dots (QD) for Advanced Retinitis Pigmentosa (RP) (QUANTUM)
Study Details
Study Description
Brief Summary
Pilot, randomized, observer and participant masked, sham and fellow eye controlled, interventional clinical device trail to evaluate the safety and effectiveness of the 2C-QD device to improve visual function in adults with advanced Retinitis Pigmentosa (RP).
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Detailed Description
Subjects will be informed about the study and potential risks and benefits, and then will provide written informed consent prior to study procedures being performed. Subjects will be screened for eligibility against criteria set forth within the clinical protocol. If subjects are eligible, they will be randomized to receive an intravitreal injection of the 2C-QD device in one eye, and the fellow eye will receive a sham injection and serve as the control. Subjects will then be following for 180 days, through 9 visits.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: 2C-QD Single-dose intravitreal injection |
Device: 2C-QD
Quantum Dot
|
| Sham Comparator: Sham 2C-QD Single-dose intravitreal injection |
Device: Sham 2C-QD
Sham Intravitreal Injection
|
Outcome Measures
Primary Outcome Measures
- Monocular navigation performance [baseline to week 2]
measured based on the ability to navigate the course under different light levels (defined as luminance) using the mobility course.
Secondary Outcome Measures
- Monocular navigation performance [baseline to week 4, 12, 24, 52]
measured using luminance level to complete the mobility course
- binocular navigation performance [baseline to week 2, 4, 12, 24, 52]
measured using luminance level to complete the mobility course
- monocular retinal sensitivity [baseline to week 2, 4, 12, 24, 52]
measured using Octopus full-field static perimetry
- monocular best-corrected visual acuity (BCVA) [baseline to week 2, 4, 12, 24, 52]
change in BCVA
- ellipsoid zone area [baseline to week 2, 4, 12, 24, 52]
measured using spectral domain (SD) optical coherence tomography (OCT)
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Male or female adults, aged 18 years or older on the day of screening
-
Clinical diagnosis of bilateral RP, based on two or more of the following: clinical features, visual field testing, retinal imaging, electrophysiological measures, or genetic testing
-
BCVA of 6/60 (logMAR 1.0) or worse in both eyes, with loss of vision due to RP in the opinion of the Investigator.
-
Central visual field of less than 20 degrees in both eyes
-
Be able to follow instructions and ambulate
-
Be able to complete at least one mobility course at highest luminance level using each eye separately
-
Be able and willing to provide written informed consent, attend all scheduled visits and comply with all study procedures
-
For females capable of becoming pregnant, agree to have urine pregnancy testing (must be negative) and must not be lactating; and must agree to use a medically acceptable form of birth control throughout the study duration. Women considered capable of becoming pregnant include all females who have experienced menarche and have not experienced menopause (as defined by amenorrhea for greater than 12 consecutive months) or have not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation, or bilateral oophorectomy). Acceptable forms of birth control are spermicide with barrier, oral contraceptive, injectable or implantable method of contraception, transdermal contraceptive, intrauterine device, or surgical sterilization of partner. For non-sexually active females, abstinence will be considered an acceptable form of birth control.
Exclusion Criteria:
-
Presence of severe systemic disease resulting in a life expectancy shorter than 1 year
-
Presence of retinal or optic nerve disease other than RP in either eye including cystoid macular oedema (CMO), glaucoma or ocular hypertension (IOPā„ 25mmHg), diabetic retinopathy, retinal vein occlusion, and age-related macular degeneration.
-
Be currently using any topical therapy for CMO (e.g., carbonic anhydrase inhibitors, corticosteroids, NSAIDs) in either eye.
-
Have the presence of an ocular media opacity in either eye, which in the opinion of the Investigator, will preclude an accurate evaluation at any time during the study
-
Have the presence of active ocular or systemic infection or inflammation, or any history of intraocular inflammation in either eye
-
Have had a prior vitrectomy in either eye
-
Have a history of amblyopia in either eye
-
Have current or former high myopia (>6 dioptres) in either eye
-
Have undergone ocular surgery within 6 months of the screening visit in either eye or have planned ocular surgery in either eye
-
Have one eye that is ineligible, or have asymmetrical ocular disease defined as a greater than 15 letter difference between the eyes based on BCVA results.
-
Have participated in any study involving an investigational drug or device within the past 30 days or have ongoing participation in a study with an investigational drug or device or have participated in a clinical trial of gene or cell therapy at any time
-
Have any clinical evidence that the Investigator feels would place the subject at increased risk with the investigational product
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- 2C Tech Corp
- ORA, Inc.
Investigators
- Principal Investigator: Timothy Jackson, Professor, Kings College Hospital
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 2C Tech-002